Efeito da terapia farmacológica anti-hipertensiva sobre densidade capilar e função endotelial microcirculatória

• Autor(a) principal: Kaiser, Sergio Emanuel
• Data de Publicação: 2012
• Tipo de documento: Tese
• Idioma: por
• Título da fonte: Biblioteca Digital de Teses e Dissertações da UERJ
• Texto Completo: http://www.bdtd.uerj.br/handle/1/12611
• topic: Microcirculation; Laser Doppler flowmetry; Endothelial function; Hypertension; Microcirculação; Fluxometria laser Doppler; Função endotelial; Hipertensão; Hipertensão; Endotélio vascular; Fatores de crescimento do endotélio vascular; CNPQ::CIENCIAS DA SAUDE::MEDICINA::CLINICA MEDICA::CARDIOLOGIA

Capillary rarefaction and microcirculatory endothelial dysfunction are hallmarks of hypertension, rendering patients vulnerable to target organ lesions. The study aimed at assessing the effect of a six-month treatment period upon capillary density and microvascular reactivity to physiological and pharmacological stimuli. In addition, two different treatment strategies were tested for possible differences between effects upon those variables. A total of 44 patients were recruited, mean age 46.7±1.3 years and 20 normotensive individuals served as controls, mean age 48.0±1.6 years. Anthropometrical and laboratory data were collected, as well as plasma levels of vascular endothelial growth factor (VEGF), its receptor Flt-1 and nitric oxide (NO). Capillary density was obtained by intra-vital microscopy of the dorsum of the middle phalanx before and after post-occlusive reactive hyperemia (PORH). Capillary loops were counted by a semi-automated software. Microvascular reactivity was tested by laser Doppler flowmetry (LDF), and the challenges consisted of acetylcholine iontophoresis, local thermal hyperemia (LTH) and PORH. Patients were randomly allocated to either one of two treatment arms: metoprolol succinate uptitrated to 100 mg daily or olmesartan medoxomil uptitrated to 40 mg daily, with addition of hydrochlorothiazide if necessary. Controls underwent the same initial protocol and all tests were repeated in patients after six months. Baseline clinical and laboratory parameters were similar between patients and controls and between the two treatment groups. After six months there were slight, although significant, differences between the two groups in waist/hip ratio and HDL-cholesterol. In the whole cohort, pretreatment capillary density was significantly reduced compared to controls (71.3±1.5 vs 80.6±1.8 cap/mm2 p<0.001 and PORH 71.7±1.5 vs 79.5±2.6 cap/mm2 p<0.05). After treatment it increased to 75.4±1.1 cap/mm2 (p<0.01) at rest and 76.8±1,1 cap/mm2 during PORH. During LTH, cutaneous vascular conductance (CVC) in perfusion units (PU)/ mmHg was similar in patients and controls and increased significantly in both subgroups (metoprolol: from 1.73±0.2 to 1.90±0.2 p<0,001 and olmesartan: from 1.49±0.1 to 1.87±0.1 p<0.001). Maximal CVC during PORH was reduced in hypertensive patients: 0.30 (0.22-0.39) compared to controls: 0.39(0.31-0.49) with p<0.001. After therapy it increased to 0.41(0.29-0.51) with p<0.001. The change was significant only for the olmesartan subgroup (from 0.29±0.02 to 0.42±0.04 p<0.001). After treatment, the difference in time spent to reach peak flow during PORH inreased significantly in patients taking metoprolol but not in those taking olmesartan: -3.0 (-8.8 to 0.2) and 0.4 (-2.1 to 2.4) seconds after vs before, respectively p<0,001. Area under the Ach iontophoresis flow curve (AUC) was similar in controls and hypertensive patients, and increased after treatment, from 6087 (3857-9137) to 7296 (5577-10921) PU/s p=0.04. VEGF and Flt-1 receptor were similar among all groups and did not change with treatment. NO levels were higher in hypertensive individuals than in controls: 64.9 (46.8-117.6) vs 50.7 (42.0-57.5) µM/dl p=0.02 and did not change with treatment. In conclusion, low-risk hypertensive patients show reduced capillary density/recruitment, and endothelial microvascular dysfunction. Both improve with treatment